VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer

Thorsten Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from the NEPAFOX trial (NCT02172976), a randomized multicenter Phase II/III study investigating adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter